Why Attend
The inaugural Phage Futures Congress 2019 in Washington D.C was the first of its kind to discuss how to translate phage-based application in to clinically and commercially viable therapeutics.
Join us in 2020 as we once again bring together over 250+ representatives from established biotech companies (from human and animal applications), new adopters, key academic researchers and big pharma. Expect to hear:
- Developments within phage applications across acute and chronic illnesses
- Regulatory discussions, including clinical trial landscape updates
- Understanding of the animal health phage applications can translate into progressing human phage therapy commercialisation
POSTER SUBMISSIONS
Looking to showcase your recent work to the phage therapy community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the evening session after the main conference on day one.
Poster abstract submission deadline is on December 20th, 2019.
Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Past attendees
TESTIMONIALS
Who Will Be There
Speakers
Dr Joe Campbell
I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group. The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.
Dr Tobi Nagel
Photo Credit: Mark Warren
Phages for Global Health is a nonprofit organization that facilitates the application of phages to combat antimicrobial resistance in developing countries. We accomplish this mission in two general ways: by delivering laboratory training workshops through which we teach scientists in developing countries how to isolate and characterize phages locally; and by partnering with developing world researchers to co-develop phage products for specific applications in their countries. Before founding Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide.
Cara Fiore
Dr. Bob Blasdel
I work as the Research Director for Vésale Bioscience where I contribute my ten years’ experience in the phage therapy field as well as my expertise in the biology of phages on a microbiological, molecular, structural, multi‘-omics’, and regulatory level. We work on progressing the personalized model of phage therapy, developing and manufacturing phages as APIs for magistral preparations according to the European model of phage therapy.
I spend a lot of time thinking about what I'm going to eat next, why cows tend to orient themselves on a north/south axis, whether viruses are alive or non-living (or undead!), what it could have really been like to have lived under the laws of Solon, structure/function arguments in biology, and the value that I like to pretend the Oxford comma has for ameliorating run-on sentences.
Carl Balibar
Dr Shawna McCallin
Nancy Tawil
Assaf Oron
Dr. Heather Jones
Dr. Jones is a pulmonary-critical care medicine specialist and physician-researcher with more than 20 years’ experience practicing medicine and conducting basic, translational and clinical research.
Dr. Jones leads Armata’s clinical development efforts with the goal of advancing its natural and synthetic phage product candidates through randomized controlled trials, supporting a path to registration. Dr. Jones continues to spend a small percentage of her time practicing critical care medicine, which allows her to remain connected to patients with life-threatening infections whom Armata is committed to helping with phage therapy.
Previously, Dr. Jones served as Director of the Lung Imaging Program, Biomedical Imaging Research Institute, and Attending physician in the medical intensive care unit at Cedars-Sinai Medical Center in Los Angeles. Her academic appointments included Associate Professor of Medicine and Biomedical Sciences at Cedars-Sinai, as well as Health Sciences Associate Clinical Professor at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Jones’s prior research focused on acute lung injury and novel lung imaging techniques. Dr. Jones has authored numerous peer-reviewed publications, delivered numerous invited presentations and received private and government grants including KL2 and K08 grants from the National Institutes of Health.
Dr. Jones earned her BA in Molecular and Cell Biology with Honors from the University of California, Berkley and a Doctor of Medicine, Magna Cum Laude, from the Medical College of Pennsylvania/Hahnemann University (now Drexel Medical School). Dr. Jones completed her residency in Internal Medicine at Boston Medical Center and her pulmonary and critical care fellowship training at Johns Hopkins Hospital, followed by an extended research fellowship at the Pulmonary Branch of the National Heart, Lung and Blood Institute.
Françoise Aubrit
Jason Gill
David Pride
David Pride’s laboratory focuses on identifying viral members of the human microbiome and in identifying their contributions to human health and disease. He is working on understanding the ecology of viruses and their consequences for our close contacts, characterizing their contributions to community antibiotic resistance, and developing model systems to understand how they respond to perturbations.
Frenk Smrekar
Dr Steven Hagens
After 22 years working with phages both in academia and industry my role is to act as interface between Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.
Dr Carl Merril
Dr. Merril, a 1962 graduate of Georgetown University Medical School studied phage biology and medical applications for over 5 decades at the NIH. His studies were inspired by participation in the Cold Spring Harbor Phage Biology Course in 1966 and they included: the interactions of phage and mammalian systems, the development of enhanced phage strains for use as antibacterial agents and the development of phage libraries as an aid in searching for phage for the treatment of individual clinical infections. An extensive, Phage library along with technologies needed to facilitate their use has recently been developed by the Naval Medical Research, Biological Defense Research Directorate and Infections Disease Departments. This technology has been licensed and a Cooperative Research Agreement has been established with Applied Phage Therapeutics (APT), a company cofounded by Dr. Carl Merril and his son , Gregory Merril, where they serve as the Chief Scientific Officer and Chief Executive Officer, respectively. The primary goal of APT and the Navy is to further the development and clinical appliations of phage, particularly for serious antibiotic resistant bacterial infections.
Matthew Tebeau
Danish Malik
Mimi Yen
Dr Biswajit Biswas
Michele Wales
Leticia Bentancor
Marie-Agnès Petit
Senior Event Partner
Proteon Pharmaceuticals
Website: http://www.proteonpharma.com
PROTEON uses bacteriophages as the foundation for preventing and eradicating infectious diseases in animals, humans and plants. Bacteriophages are naturally occurring organisms in the microbiome.
Bacteriophages offer an exciting alternative to antibiotics in combating pathogenic bacteria including antibiotic resistant microbes (AMR). PROTEON’s therapeutic products are safe for human, animals and plants and are based on environmentally sustainable methods and approaches.
We have developed a unique phage-platform using proprietary tools and expertise in microbiology, DNA sequencing and bioinformatics. Our phage-platform enables continued discovery of new solutions for a wide variety of industries and applications.
Event Partners
Cellexus
Website: http://www.cellexus.com/
Cellexus was established in 2008, to develop a scalable single use bioreactor (SUB) for industrial and academic scientists to grow cell cultures in their laboratories, rapidly and in a controlled environment, for use in a wide range of applications including life sciences, brewing, biopharmaceutical and agricultural feed.
Clean Cells
Website: https://clean-cells.com/
Clean Cells offers a comprehensive service portfolio ranging from test for viral and biological safety of biopharmaceuticals, the production of cell and virus banks that are GMP grade and secure storage, as well as the production of experimental drugs such as cell therapy products and therapeutic phages. Clean Cells aims to become a major role in the development of new therapies to revolutionize personalized medicine.
PHAGE: Therapy, Applications, and Research
Website: https://home.liebertpub.com/publications/phage/652
PHAGE: Therapy, Applications, and Research is the only peer-reviewed journal dedicated to fundamental bacteriophage research and its applications in medicine, agriculture, aquaculture, veterinary applications, animal production, food safety, and food production.
Under the leadership of Editor-in-Chief Martha Clokie, PhD, University of Leicester, the Journal showcases groundbreaking research, reviews, commentaries, opinion pieces, profiles, and perspectives dedicated to defining the roles of phages in all facets of microbiology and microbial ecology and exploring their potential to manipulate bacterial communities and treat infection.
JAFRAL
Website: https://jafral.com/
JAFARAL is world’s leading CMO for production of bacteriophages, because it’s has more than 10 years’ experience in manufacturing of phages, other biologics production, large scale production and knowing GMP guidelines. Likewise, JAFRAL has all these years also been involved in plasmid DNA and recombinant proteins production at various levels. JAFRAL’s custom development and manufacturing services have helped developers across the globe to accelerate research and open up their laboratories for ground-breaking science and breakthrough discoveries.
Myriade
Website: http://www.myriadelab.com/en/
Myriade is a French company created in 2017 that develops an innovative nanoscale imaging technology: the VIDEODROP
Based on the principles of interferometry, the Videodrop makes it possible to visualize living nanoparticles in the range of 30 nm and 10 microns without labeling, in real time and in a single drop.
The Videodrop processing algorithms compute the concentration and size distribution of the nanoparticles and enable to analyze complex mixtures of phages (T4, lambda) for applications in phagotherapy, continuously monitor viral vector solutions (Lentiviruses, adenoviruses) for gene and cell therapy, and distinguish the different types of EVs to vectorize, diagnose or treat
Phagelux
Website: http://www.phagelux.com/
Lead Media Partner
Phage Directory
Phage Directory promotes and accelerates the safe and effective use of phages in medicine, agriculture, and biotechnology around the world. We provide insight and support to communities and organizations interested in understanding and using phages.
Phage Directory can support you to:
- Stay up-to-date on new developments in phage research and phage therapy
- Understand the regulatory, scientific and tech landscape around phages and phage therapy
- Find and recruit individuals with phage expertise
- Develop phage-based technologies and products
- Organize phage and phage therapy-related conferences, seminars and workshops
The Agenda
Fill in your details to download a copy of the 2020 Phage Futures Congress agenda to see all topics being covered and why you should attend.
Agenda launched!
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Venue
Hilton McLean Tysons Corner, 7920 Jones Branch Drive, McLean, VA, 22102-3308
This year The Phage Futures Congress returns to Hilton McLeant Tysons Corner.
Room rate: $229.00 exclusive of applicable state and local taxes, fees and assessments (double room)
Book now: https://book.passkey.com/go/PhageFuturesCongress
Book by 10 January 2019 to benefit from this exlcusive rate.
After this date rates are subject to availability.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.